You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News and reporting on melanoma.
The La Jolla, California-based developer of genomic melanoma tests posted nearly $1.6 million in revenues in Q4, up from $600,000 in Q4 2018.
The skin cancer diagnostics company said it delivered 37 percent more DecisionDx-Melanoma test results in Q4 2019 than in the previous year's fourth quarter.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The Medicare Administrative Contractor will provide limited coverage for the RNA gene expression test that helps rule out primary cutaneous melanoma.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.
The company said it delivered 4,480 DecisionDx-Melanoma test reports in Q4 2019 compared to 3,270 reports in Q4 2018.
The LCD for the RNA gene expression test will take effect on Feb. 10, 2020, the Medicare contractor said.
Palmetto has expanded the local coverage determination for the Guardant360 liquid biopsy assay to be used with the majority of advanced solid tumors.
The firm has begun a trial for tests in non-small cell lung cancer and malignant melanoma and plans to launch an additional trial in glioblastoma.